Caliway Biopharmaceuticals Co. L
6919
Rangering i aksjer
#4340
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Aksjekurs
$2.29
Markedsverdi
$3.56B
Endring (1 dag)
-2.50%
Endring (1 år)
-57.22%
Land
TW
Handel Caliway Biopharmaceuticals Co. L (6919)
Kategori
Healthcare
Aksjeprishistorikk for Caliway Biopharmaceuticals Co. L (6919)
Høyeste sluttskurs: $2.44 den 2026-10-01
Laveste sluttskurs: $0.20 den 2022-12-01
Laveste sluttskurs: $0.20 den 2022-12-01
Aksjeprishistorikk for Caliway Biopharmaceuticals Co. L fra 2022 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | -25.32% |
| 2025 | 190.26% |
| 2024 | 181.33% |
| 2023 | 210.73% |
| 2022 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $530.66 | 24.44% |
US
|
|
| $230.18 | 757.28% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.66 | 9.40% |
NL
|
|
| $290.41 | 2.03% |
BE
|
